Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors: Phase II Study of Chemotherapy, Surgery, Photon and Heavy Ion Radiotherapy Integration for More Effective and Less Toxic Treatment in Operable Patients

Status: Unknown
Location: See all (5) locations...
Intervention Type: Drug, Radiation
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Sinonasal tumors are rare diseases, so no standard treatment for such aggressive tumors has been reported, given rarity, absence of prospective study and heterogeneity of histologies and stages of diseases. This study proposes innovative integration of multiple modality of treatment depending by histology, molecular profile and response to induction CT. Moreover, such strategies allows the use of latest technology with greater biological effectiveness and reduction of toxicities.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Signed and dated IEC-approved Informed Consent

• Diagnosis of sinonasal tumor with the following histotypes:

‣ Squamous Cell Carcinoma (SCC);

⁃ Sinonasal Undifferentiated Carcinoma (SNUC);

⁃ Small Cell Carcinoma Neuroendocrine Type (SmCCNET);

⁃ Pure Sinonasal Neuroendocrine Carcinoma (SNEC);

⁃ Intestinal Type Adenocarcinoma (ITAC) with a functional p53 gene;

⁃ Esthesioneuroblastoma with differentiation grade III-IV by Hyams The inclusion of the maxillary sinus carcinomas is reserved only in cases requiring exenteratio orbitae for a radical surgery.

• AJCC stage II-III-IVa with the exception of Esthesioneuroblastoma and Intestinal Type Ethmoid Adenocarcinoma where stage III-IV only will be included.

• Resectable disease.

• ECOG performance status 0-2.

• Adequate bone marrow, renal and hepatic functionality, defined as haemoglobin \>10 g/dL, neutrophils \>1500/mmc, platelets \> 100.000/mmc, creatinine value ≤ 1.5 x ULN or calculated creatinine clearance (by Cockcroft and Gault's formula) \> 60 mL/min, transaminases values \< 1.5 times over the upper normal limit (ULN).

• Polychemotherapy treatment clinical feasibility as per Investigator's Judgment.

• Male or female patients ≥ 18 years of age.

• Negative pregnancy test (if female in reproductive years).

⁃ Agreement upon the use of effective contraceptive methods (hormonal or barrier method of birth control, or abstinence) prior to study entry and for the duration of study participation, if men and women of child producing potential.

Locations
Other Locations
Italy
Presidio Ospedaliero Spedali Civili di Brescia
Brescia
Fondazione IRCCS Istituto Nazionale Tumori
Milano
Azienda Ospedaliera Maggiore della Carità
Novara
IRCCS Policlinico San Matteo
Pavia
A.O. Ospedale di Circolo e Fondazione Macchi
Varese
Time Frame
Start Date: 2013-11
Completion Date: 2024-01
Participants
Target number of participants: 41
Treatments
Experimental: Multimodality treatment
Squamocellular Carcinoma, Sinonasal Undifferentiated Carcinoma:~* Docetaxel at 75 mg/m2 as IV infusion on Day 1 q3w~* Cisplatin at 80 mg/m2 as IV infusion on Day 1 q3w~* 5-fluorouracil at 800 mg/m2/day as IV infusion from Day 1 to Day 4 q3w~Small cell carcinoma neuroendocrine type, Pure neuroendocrine carcinoma and grade III-IV Esthesioneuroblastoma:~First Cycle and every other cycle:~* Cisplatin at 33 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~* Etoposide at 150 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Second Cycle and every other cycle:~* Adriamycin at 20 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~* Ifosfamide at 3000 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Intestinal Type Adenocarcinoma with functional p53:~* Leucovorin\* at 250 mg/m2/day as IV infusion from Day 1 to Day 5 q3w~* Cisplatin at 100 mg/m2 as IV infusion on Day 2 q3w~* 5-fluorouracil at 800 mg/m2/day as IV infusion from Day 2 to Day 5 q3w~Followed by Radiotherapy
Sponsors
Collaborators: Regione Lombardia
Leads: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

This content was sourced from clinicaltrials.gov